Back to search
Pancreas Adenocarcinoma (MSI-H)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Pancreas Adenocarcinoma (MSI-H) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Pancreas Adenocarcinoma (MSI-H) trials you may qualify forA phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of…
INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as…
Pancreatic adenocarcinoma (PA) is the most common tumor of the pancreas. Given its poor prognosis and the major therapeutic consequences, the discrimination bet…